Go online to PeerView.com/EPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Statin therapy is the cornerstone treatment for dyslipidemia, yet many patients are unable to attain recommended lipid goals with these oral therapies alone. PCSK9-targeting therapies, including monoclonal antibodies and small-interfering RNA, have been shown to reduce LDL-C levels by half, but questions surround the use of these agents and their associated outcomes. In this activity, based on a recent live symposium, leading experts discuss the latest data for these newer targeted therapies and offer evidence-based strategies to better individualize care to improve clinical outcomes, especially in patients with high ASCVD risk. Apply treatment guidelines for the management of hyperlipidemia, for both primary and secondary prevention of cardiovascular events, in patients with ASCVD; Identify the latest clinical evidence, mechanisms of action, and cardiovascular outcomes of approved and emerging non-statin, lipid-lowering therapies, especially PCSK9-targeting agents for managing hyperlipidemia in the ASCVD setting; and Individualize treatment regimens to reduce cardiovascular events in high-risk patients with hyperlipidemia consistent with consensus recommendations and recent clinical evidence available for novel lipid-lowering therapies.
PeerView Internal Medicine CME/CNE/CPE Audio Podcast